MicrobiotiX completes MP101 Phase 1 sentinel cohort

MicrobiotiX reported completion of the sentinel cohort in its Phase 1 MP101 trial for Pseudomonas aeruginosa pneumonia. The initial 72-hour assessment raised no safety concern that prevented continuation, and Cohort 1 enrollment was proceeding as planned.